PKCδ inhibition interfered with the clonogenicity of primary CML CD34+ and BCR-ABL-transduced healthy CD34+ cells as efficiently as any TKI while it did not affect differentiation of healthy CD34+ cells. The gene discussed is PRKCD; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.